Rare diseases
Investigational molecules
Locations
Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma
The NetherlandsStudy on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients
The NetherlandsPhase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease
The NetherlandsA Phase 1/2 study of CHM-029 alone and in combination drug regimen in adults with newly diagnosed, relapsed or refractory Acute Myeloid Leukemia
The NetherlandsA Phase 2 Study of MZE782 Safety, Tolerability, and Efficacy in Adults with Phenylketonuria
The NetherlandsStudy of [18F]MC225 PET to Assess Blood‑Brain Barrier Function in Patients with Suspected Glioblastoma
The NetherlandsEfficacy and safety of ontunisertib in patients with fibrostenosing Crohn’s disease: a phase 2b randomized, double‑blind, placebo‑controlled dose‑ranging trial
The NetherlandsRamantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant
The NetherlandsA study of NNC0638-0355 to evaluate safety, tolerability and weight loss with multiple doses in adults with obesity or overweight
The NetherlandsStudy of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy
The NetherlandsFluorescence bronchoscopy to assess durvalumab-680LT distribution in unresectable stage III non‑small cell lung cancer patients after chemoradiation
The NetherlandsEpcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma
The NetherlandsTell us about your condition – we search every trial in Europe and connect you with the right site.
